$0.64
5.88% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US70387R1068
Symbol
PAVM

PAVmed, Inc. Stock price

$0.64
-0.08 11.70% 1M
-0.13 16.49% 6M
+0.01 1.75% YTD
-0.47 42.48% 1Y
-28.84 97.83% 5Y
-167.44 99.62% 10Y
-167.44 99.62% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.04 5.88%
ISIN
US70387R1068
Symbol
PAVM
Sector

Key metrics

Market capitalization $11.73m
Enterprise Value $15.29m
P/E (TTM) P/E ratio 0.49
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.68
P/S ratio (TTM) P/S ratio 5.90
P/B ratio (TTM) P/B ratio 0.24
Revenue growth (TTM) Revenue growth -34.11%
Revenue (TTM) Revenue $1.99m
EBIT (operating result TTM) EBIT $-35.90m
Free Cash Flow (TTM) Free Cash Flow $-22.05m
Cash position $3.05m
EPS (TTM) EPS $1.38
P/E forward 3.77
P/S forward 80.07
EV/Sales forward 104.37
Short interest 2.46%
Show more

Is PAVmed, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

PAVmed, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a PAVmed, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a PAVmed, Inc. forecast:

Buy
100%

Financial data from PAVmed, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.99 1.99
34% 34%
100%
- Direct Costs 3.13 3.13
54% 54%
157%
-1.14 -1.14
70% 70%
-57%
- Selling and Administrative Expenses 30 30
33% 33%
1,497%
- Research and Development Expense 4.78 4.78
61% 61%
240%
-36 -36
41% 41%
-1,794%
- Depreciation and Amortization 0.19 0.19
90% 90%
10%
EBIT (Operating Income) EBIT -36 -36
43% 43%
-1,804%
Net Profit 72 72
202% 202%
3,641%

In millions USD.

Don't miss a Thing! We will send you all news about PAVmed, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PAVmed, Inc. Stock News

Neutral
PRNewsWire
11 days ago
Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK , June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority...
Neutral
PRNewsWire
18 days ago
NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 2...
Neutral
Seeking Alpha
29 days ago
PAVmed Inc. (NASDAQ:PAVM ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director of Investor Relations Lishan Aklog - Chairman and Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Jeremy Pearlman - Maxim Group Edward Woo - Ascendiant Capital Operator Good morning, and welcome to the PAVmed's First ...
More PAVmed, Inc. News

Company Profile

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Head office United States
CEO Lishan Aklog
Employees 39
Founded 2014
Website pavmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today